J. Safra Sarasin Holding AG Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

J. Safra Sarasin Holding AG boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 69.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,142 shares of the biopharmaceutical company's stock after buying an additional 7,868 shares during the period. J. Safra Sarasin Holding AG's holdings in Alnylam Pharmaceuticals were worth $4,504,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ALNY. Jennison Associates LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $61,160,000. Strategic Financial Concepts LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $41,529,000. Truist Financial Corp lifted its position in Alnylam Pharmaceuticals by 136.6% during the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after purchasing an additional 2,539 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 3.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after acquiring an additional 8,462 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Alnylam Pharmaceuticals by 13.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after purchasing an additional 2,285 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 3.7 %

Shares of NASDAQ:ALNY traded up $8.95 on Friday, reaching $251.56. The company had a trading volume of 835,531 shares, compared to its average volume of 876,125. The firm has a market capitalization of $32.72 billion, a PE ratio of -115.93 and a beta of 0.30. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The firm's 50 day simple moving average is $247.34 and its 200-day simple moving average is $256.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ALNY shares. HC Wainwright reiterated a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. StockNews.com upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday. Chardan Capital restated a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Sanford C. Bernstein dropped their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Finally, JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $280.00 to $328.00 in a report on Monday, March 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $315.58.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 1,213 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 59,984 shares of company stock valued at $16,864,347. Corporate insiders own 1.20% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.